A Study of Qishenyiqi Dripping Pills in Healthy Participants

Overview

This study will evaluate the safety and tolerability of Qishenyiqi Dripping Pills in healthy participants, following oral administration with multiple escalating dose of it.

Full Title of Study: “A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Evaluate the Safety and Tolerability of Continuous Oral Treatment With Qishenyiqi Dripping Pills in Healthy Participants”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: January 11, 2021

Detailed Description

Qishenyiqi dripping pills, which are made of Huangqi, Danshen, Sanqi, active ingredients of Jiangxiang, have the efficacy of beneficial effects of qi and pulse, blood circulation and pain relief. This study is a randomized, double-blind, placebo-controlled, dose-escalation design study, including three cohorts and 36 healthy participants. Within each cohort, participant will receive Qishenyiqi dripping pills at the selected dose level by oral administration three times a day for 28 consecutive days.

Interventions

  • Drug: Qishenyiqi dripping pills, 6 bags
    • 28 consecutive days
  • Drug: Qishenyiqi dripping pills, 9 bags
    • 28 consecutive days
  • Drug: Qishenyiqi dripping pills, 12 bags
    • 28 consecutive days
  • Drug: Qishenyiqi dripping pills placebo, 6 bags
    • 28 consecutive days
  • Drug: Qishenyiqi dripping pills placebo, 9 bags
    • 28 consecutive days
  • Drug: Qishenyiqi dripping pills placebo, 12 bags
    • 28 consecutive days

Arms, Groups and Cohorts

  • Active Comparator: Active dosage group 1
    • Qishenyiqi dripping pills, 3.12g, oral, three times a day
  • Active Comparator: Active dosage group 2
    • Qishenyiqi dripping pills, 4.68g, oral, three times a day
  • Active Comparator: Active dosage group 3
    • Qishenyiqi dripping pills, 6.24g, oral, three times a day
  • Placebo Comparator: Control dosage group 1
    • Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day
  • Placebo Comparator: Control dosage group 2
    • Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day
  • Placebo Comparator: Control dosage group 3
    • Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day

Clinical Trial Outcome Measures

Primary Measures

  • Adverse events
    • Time Frame: From screening (2 weeks in advance) till follow-up visit (up to 1week)
    • Observe all the adverse events of all participants administrated orally with Qishenyiqi dripping pills.
  • Number of participants with abnormal vital signs index (body temperature)
    • Time Frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal vital signs index (pulse rate)
    • Time Frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal vital signs index (respiratory rate)
    • Time Frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal vital signs index (blood pressure)
    • Time Frame: From screening (2 weeks in advance) till the end of trial period (Day 29)
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Physical examination
    • Time Frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
    • The complete physical examinations will include an assessment of the general appearance, skin, cardiovascular, abdomen, head, and neck, lymph nodes, musculoskeletal and neurological systems.
  • Number of participants with abnormal laboratory assessments (blood routine test)
    • Time Frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal laboratory assessments (blood biochemical test)
    • Time Frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal laboratory assessments (coagulation function test)
    • Time Frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal laboratory assessments (urinalysis routine test)
    • Time Frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal laboratory assessments (fecal routine test)
    • Time Frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.
  • Number of participants with abnormal findings in 12-lead safety Electrocardiogram (ECG)
    • Time Frame: screening (2 weeks in advance), Day 8, Day 15, Day 22, Day 29
    • To investigate the safety and tolerability of Qishenyiqi dripping pills following oral administration in healthy participants.

Participating in This Clinical Trial

Inclusion Criteria

  • Healthy volunteers, male or female, aged 18-50 years (including the boundary value); – Participants weigh at least 50.0 kg in male and 45.0 kg in female with a body mass index of all subjects between 19 and 26kg/m2 (including the boundary value); – Participants are willing to have no pregnancy program and take effective contraceptive measures voluntarily since signing informed consent form to 3 months after the last administration; – Participants are willing to sign Independent Ethics Committee (IEC)-approved informed consent form and able to understand and comply with study procedures. Exclusion Criteria:

  • Participants with allergic constitution or have a history of allergy to drug or food; – Participants with diseases or physiological conditions that may affect the study, including but not limited to diseases of the nervous, mental, respiratory, cardiovascular, digestive, blood and lymphatic, endocrine, musculoskeletal systems, liver and kidney dysfunction; – Participants who have any clinically significant abnormalities in vital signs, physical examination, electrocardiogram, chest radiograph, abdominal ultrasound and laboratory examination; – Participants who have positive test for hepatitis B virus surface antigen (except surface antibodies), hepatitis C virus antibody, human immunodeficiency virus antibody and treponema pallidum antibody; – Women who are in the state of pregnancy or lactation; – Participants who have a history of drug abuse or a positive test result for drug abuse at screening; – Participants who have smoked more than 5 cigarette per day or used a considerable amount of nicotine-containing products within the previous 3 months, and could not quit smoking during the experiment; – Participants who have been drinking more than 14 units of alcohol per week within the previous 3 months (1 unit ≈285 mL beer with 3.5% alcohol or 25 mL spirits with 40% alcohol or 85 mL wines with 12% alcohol), or positive test for alcohol, or could not abstain from drinking during the trial; – Participants who have taken any prescription drugs (including prescription, nonprescription, herbal medicine, dietary supplement such as vitamin product and calcium tablet) within 4 weeks before administration of investigational drugs; – Participants who have difficulty in venous blood collection or history of fainting blood or needles; – Participants who have participated in any drug clinical trial within 3 months and have taken the experimental drug or plan to participate in other clinical trials during the trial period; – Participants who have donated or lost blood ≥200 mL within 3 months or received blood transfusion or used blood products, or have blood donation plan during the trial period; – Judged by the investigator, participants have poor compliance or have other factors such as clinical, social or family that should not be included in the trial.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Tasly Pharmaceutical Group Co., Ltd
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.